[Effects of beta-adrenergic agonists on alveolar fluid clearance in rat lungs].
OBJECTIVE
To study the effects of three selective beta-adrenergic agonists on alveolar fluid clearance (AFC) in the isolated rat lungs.


METHODS
Isotonic 5% albumin solutions with different pharmacological agents were instilled into the distal airways in the isolated rat lungs. The lungs were inflated with 100% oxygen at 7 cm H2O (1 cm H2O = 0.098 kPa) and placed in a humid incubator at 37 degrees C. AFC was estimated by the progressive increase in the albumin concentration over 1 h.


RESULTS
The baseline AFC was 6.9% +/- 2.2%. Beta(1)-adrenergic agonist denopamine, beta(2)-adrenergic agonist terbutaline and beta(3)-adrenergic agonist BRL-37344 increased AFC significantly (17.1% +/- 2.4%, 19.5% +/- 1.2% and 19.9% +/- 2.5%, respectively). Beta(1)-adrenergic antagonist atenolol abolished the effects of denopamine (AFC was 6.1% +/- 0.9%), but did not inhibit the effects of terbutaline and BRL-37344. Beta(2)-adrenergic antagonist ICI-118551 abolished the effects of terbutaline and BRL-37344 (AFC were 5.7% +/- 0.6% and 7.8% +/- 2.6%), and also partially inhibited the effects of denopamine (AFC was 12.7% +/- 1.8%). Beta(3)-adrenergic antagonist SR-59230A partially inhibited the effects of BRL-37344 and terbutaline (AFC were 13.8% +/- 3.1% and 14.5% +/- 3.5%), but did not change the effects of denopamine.


CONCLUSIONS
Denopamine, terbutaline and BRL-37344 are potent stimulators of AFC in the rat lungs. The effects of denopamine and terbutaline are mediated via beta(1)- and beta(2)-adrenoceptors, respectively. The effects of BRL-37344 may be mediated via beta(2)-adrenoceptors. ICI-118551 and SR-59230A may have some beta(1)- and beta(2)-inhibitory effects, respectively.
Gu
Xiu
X
Department of Respiratory Medicine, Second Affiliated Hospital, China Medical University, Shenyang 110004, China.
Li
Sheng-qi
SQ
Sakuma
Tsutomu
T
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D004983:Ethanolamines / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D011412:Propanolamines / Q000494:pharmacology; D011650:Pulmonary Alveoli / Q000187:drug effects* / Q000378:metabolism*; D011654:Pulmonary Edema / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
C097869:3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate; D000318:Adrenergic beta-Agonists; D004983:Ethanolamines; D011412:Propanolamines; C057368:BRL 37344